Medical Marijuana, Inc. MJNA

Company Overview

Medical Marijuana, Inc. is a U.S.-based cannabis and hemp-focused holding company that develops, markets, and distributes products derived primarily from industrial hemp. The company operates in the broader cannabis wellness, nutraceutical, personal care, and cannabinoid consumer products industries, with a strategic focus on cannabidiol (CBD) and related hemp-derived compounds. Its revenue has historically been driven through the sale of hemp-based dietary supplements, wellness products, cosmetics, and cannabinoid ingredients distributed through subsidiaries and affiliated brands. The company has also pursued licensing, international distribution, and investment activities tied to the legal cannabis and hemp sectors.

The company was founded in 2009 and became one of the earliest publicly traded cannabis-related companies in the United States through over-the-counter markets. Over time, Medical Marijuana, Inc. evolved from a broad cannabis investment and development platform into a holding company centered on hemp-derived consumer products and cannabinoid research initiatives. The company has emphasized early-mover positioning in hemp-derived CBD products, particularly before broader regulatory acceptance in the U.S. market. Public disclosures and corporate filings indicate that the company has focused on brand development, international expansion, and scientific validation of cannabinoid applications.

Business Operations

Medical Marijuana, Inc. operates primarily through several subsidiaries and branded business units, including Kannaway, HempMeds, and Kannaway Brasil. These businesses market and distribute hemp-derived CBD products such as tinctures, capsules, topical products, skincare items, and wellness supplements. Historically, the company has used direct-selling and network marketing models through Kannaway, while HempMeds has focused on broader consumer and distributor channels. Revenue generation has largely depended on product sales, distributor networks, and international market expansion tied to hemp-derived wellness products.

The company’s operations extend beyond the United States into international markets, particularly in Latin America and parts of Europe. Medical Marijuana, Inc. has highlighted proprietary hemp formulations, sourcing relationships, and cannabinoid extraction capabilities as strategic operational assets. Public disclosures have also referenced research collaborations and commercial partnerships aimed at supporting cannabinoid science and market penetration. The company has maintained involvement in cannabinoid-related intellectual property, formulation development, and regulatory market entry efforts, though available public information indicates that its operating scale remains modest relative to larger cannabis industry participants.

Strategic Position & Investments

Medical Marijuana, Inc.’s strategic direction has focused on expanding hemp-derived cannabinoid wellness products into regulated international markets while building consumer awareness around CBD-based health and wellness applications. The company has historically emphasized first-mover advantages in hemp-derived CBD distribution, particularly before the mainstream commercialization of CBD products following changes in U.S. hemp legislation. Growth initiatives have included international direct sales expansion, product portfolio diversification, and investment in cannabinoid education and research.

The company has also pursued acquisitions and ownership interests in cannabis-related businesses and intellectual property over time. Subsidiaries such as Kannaway and HempMeds have represented core operational assets within the corporate structure. Public filings and investor materials have referenced involvement in emerging cannabinoid sectors including nutraceuticals, cosmeceuticals, and pharmaceutical-adjacent research initiatives. The company has also emphasized participation in international cannabinoid regulatory development, particularly in countries where medical cannabis and CBD frameworks are evolving. Some claims regarding market leadership and proprietary positioning vary across public disclosures, and certain operational details are difficult to independently verify through current public sources.

Geographic Footprint

Medical Marijuana, Inc. is headquartered in California, United States, and operates across multiple international markets through subsidiaries, distribution relationships, and direct-selling channels. The company’s historical core market has been the United States, particularly within the hemp-derived CBD consumer wellness sector. Through Kannaway and affiliated operations, the company has expanded into regions including Brazil, Mexico, and parts of Europe.

Internationally, the company has focused on markets with developing cannabinoid regulatory structures and growing demand for hemp-derived wellness products. Public disclosures have highlighted activity in Latin America, especially Brazil, where cannabinoid-based medical products have experienced increasing regulatory acceptance. The company’s international strategy has generally centered on distributor-led expansion and localized regulatory engagement rather than large-scale cultivation or manufacturing infrastructure ownership outside the United States.

Leadership & Governance

Medical Marijuana, Inc. was founded during the early development phase of the legal cannabis industry in the United States and has undergone multiple leadership transitions as the sector matured. The company’s governance structure reflects its role as a publicly traded holding company with oversight across several cannabinoid-focused subsidiaries and international operations. Corporate strategy has emphasized regulatory adaptation, brand expansion, and long-term positioning within hemp-derived wellness markets.

Key executives identified in recent public filings and corporate disclosures include:

• Blake Schroeder – Chief Executive Officer
• Douglas C. Winfrey – Chief Operating Officer
• Todd Morrow – General Counsel
• Mark Toomey – Chief Financial Officer

Management communications and investor materials indicate that leadership has prioritized international growth, cannabinoid product commercialization, and scientific validation of hemp-derived compounds. Governance and financial reporting information has primarily been disclosed through SEC filings, OTC market disclosures, and company investor communications. Some executive role histories and organizational details vary across reporting periods, reflecting changes in corporate structure and management over time.